Target intelligence / Profile preview

Interleukin-21 receptor subunit alpha (IL-21R)

Target
IL-21R
Molecular classification
Receptor, Type I cytokine receptor, CD antigen
01

Overview

Interleukin-21 receptor subunit alpha (IL-21R, also known as CD360) is a type I cytokine receptor subunit that forms a functional heterodimeric complex with the common gamma chain (IL-2RG) to bind and transduce signals for interleukin-21 (IL-21). It is predominantly expressed on the surface of immune cells, including T cells, B cells, natural killer (NK) cells, and dendritic cells. Upon ligand binding, IL-21R recruits and activates Janus kinases JAK1 and JAK3, which subsequently phosphorylate and activate STAT3, STAT1, and STAT5 transcription factors, driving immune cell proliferation, differentiation, and effector functions.

The IL-21/IL-21R axis plays a dual role in human pathology: overactivation is associated with autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), while its activation is critical for anti-tumor immunity and viral clearance. Consequently, therapeutic strategies target this receptor in two opposing ways: IL-21R antagonists (such as the monoclonal antibody ATR-107) are developed to suppress aberrant immune responses in autoimmunity, whereas IL-21R agonists (such as denenicokin, latikafusp, and ANV700) are designed to boost cytotoxic T cell and NK cell activity in cancer immunotherapy. However, clinical development has faced challenges, including high immunogenicity and hypersensitivity reactions for antagonists, and systemic toxicities or immune exhaustion for agonists.

Other names
Interleukin-21 receptorIL-21 receptorIL-21R-alphaCD360Novel interleukin receptorNILRIMD56
02

Mechanism of action

Interleukin-21 receptor antagonist, Interleukin-21 receptor agonist, Activation of JAK/STAT signaling pathway, Inhibition of IL-21/IL-21R signaling pathway

03

Biological functions

Immune responseCell proliferationCell differentiationSignal transductionT-cell activationB-cell differentiationNK cell activation
04

Disease associations

Autoimmune diseaseInflammationCancerInfectionSystemic lupus erythematosusRheumatoid arthritis
05

Safety considerations

Hypersensitivity reactionsImmunogenicityAnti-drug antibody formationCytokine release syndromeAutoimmune reactionsInfectionsNeutropeniaLymphopeniaAnemiaElevated transaminases
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

IL-21R expressionSTAT3 phosphorylationSTAT1 phosphorylationSoluble CD25Interferon-gamma levelsB cell receptor occupancy

Beyond the preview

Go deeper on Interleukin-21 receptor subunit alpha (IL-21R).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin-21 receptor subunit alpha (IL-21R).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call